I-Mab ADR (IMAB)

$4.63 -0.01 (-0.22%)
Market Cap 378.09M
Revenue (ttm) 0.00
Net Income (ttm) -22.23M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,517,300
Avg Vol 1,822,668
Day's Range N/A - N/A
Shares Out 81.66M
Stochastic %K 22%
Beta 1.45
Analysts Strong Sell
Price Target $8.60

Company Profile

I-Mab, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to resear...

Industry: Biotechnology
Sector: Healthcare
Phone: 240 745 6330
Address:
2440 Research Boulevard, Suite 400, Rockville, United States
sgtcw1
sgtcw1 Jun. 29 at 12:31 PM
$IMAB https://finance.yahoo.com/healthcare/articles/novabridge-biosciences-appoints-dr-srishti-110000448.html
0 · Reply
Jstidd
Jstidd Jun. 16 at 12:41 PM
$IMAB Givastomig fast track designation this AM https://www.globenewswire.com/news-release/2026/06/16/3312417/0/en/novabridge-biosciences-receives-fda-fast-track-designation-for-givastomig-in-first-line-her2-negative-metastatic-gastric-cancer.html
1 · Reply
Stocksman45
Stocksman45 Jun. 10 at 5:09 PM
$IMAB HC Wainright reiterates buy with target to $9. Accelerated Givastomig to phase 3 possibly by last quarter 2026. Already have a position, but getting interesting to add more. Once good results in phase 3, the risk reduces to make this a true biotech.
1 · Reply
Stocksman45
Stocksman45 Jun. 6 at 12:02 PM
$IMAB Nice that they look like they are skipping to phase 3 for Givastomig. Possibly by year end. “Givastomig, a potential best-in-class/first-in-class Claudin 18.2-directed bispecific antibody for gastric cancer, has shown robust and durable responses with broad CLDN18.2 activity, favorable safety, as well as potential eligibility for FDA’s Accelerated Approval Pathway with potential initiation of a registrational Phase 3 trial as early as Q4 2026.”
0 · Reply
GamblingFerret
GamblingFerret Jun. 6 at 11:25 AM
$IMAB Partner ABL Bio has initiated Ragistomig combination cohort (Phase 1)
0 · Reply
GamblingFerret
GamblingFerret Jun. 3 at 7:49 PM
$IMAB Tomorrow at Jefferies Healthcare Conference. I would not be surprised if we get Q1 results today after hours or tomorrow pre-market.
0 · Reply
GamblingFerret
GamblingFerret May. 29 at 10:25 PM
$IMAB Even though Nova is not at ASCO, there are still potential triggers. https://www.asco.org/annual-meeting/search?filters=%7B%22mediaTypes%22:%5B%22Abstracts%22%5D%7D&userInput=Claudin%2018.2&sortBy=AbstractBrowse&contentKey=ANNUAL_MEETING&contentKeyYear=2026 Multiple presentations of Claudin 18.2 ADCs, combinations and Bispecifics. I checked them quickly, benefits for Giva in PFS, ORR, safety and low claudin concentration depending on competitors. Hope with quarterly report we receive an update from 12mg cohort, especially on PFS which will most likely exceed the 16.9 months from 8mg cohort based on 6 month landmark. As reminder: https://www.novabridge.com/news-releases/news-release-details/novabridge-presents-positive-givastomig-dose-expansion-data Overall it looks like Giva prooves to be best in class with broadest spectrum.
1 · Reply
GamblingFerret
GamblingFerret May. 20 at 5:49 AM
$IMAB Worth listening to HC Wainwright fireside chat with focus on Giva Nova finalizes Giva Phase 3 design and intends to start in Q4. Interesting comment from Sean, I expect a partnering after design approval and update of running extension cohorts. Interesting as well: They are evaluating to start a Claudin 18.2 negativ cohort given the strong performance of Giva in low CLD 18.2 patient and test inaccuracy in extreme low settings. This would add additional 25-30% of total market opportunity. Double low, BTC and PDAC chorts recruiting well with data expected YE.
1 · Reply
LabPsycho
LabPsycho May. 15 at 8:12 PM
$IMAB @Tika1 @jayshree4201Twits Unless nobody cares. I am not seeing any huge differentiator with their data...looks good but going to need more than that IMO. And this opinion applies to many biotechs - while it might seem early, some of these that have drifted down since the beginning of the year I see more downward movement motivated by: Summer doldrums (sell in May then go away) Blips in June (ASCO conference spiking 1 or 2) Drifting down more Spikes in Sept (transient for a few) Nov. Tax loss selling I could see NBP IMAB getting down to 1.2 by then. Dec - Feb 2027 some up 100-200% if one times the bottom perfectly + a bit of luck
1 · Reply
jayshree4201Twits
jayshree4201Twits May. 11 at 7:20 PM
$IMAB Anyone still around for this stock? Since NBP is taken, seems like no one is holding this. Anyone has any thought they can share regarding current movement?
2 · Reply
Latest News on IMAB
No data available.
sgtcw1
sgtcw1 Jun. 29 at 12:31 PM
$IMAB https://finance.yahoo.com/healthcare/articles/novabridge-biosciences-appoints-dr-srishti-110000448.html
0 · Reply
Jstidd
Jstidd Jun. 16 at 12:41 PM
$IMAB Givastomig fast track designation this AM https://www.globenewswire.com/news-release/2026/06/16/3312417/0/en/novabridge-biosciences-receives-fda-fast-track-designation-for-givastomig-in-first-line-her2-negative-metastatic-gastric-cancer.html
1 · Reply
Stocksman45
Stocksman45 Jun. 10 at 5:09 PM
$IMAB HC Wainright reiterates buy with target to $9. Accelerated Givastomig to phase 3 possibly by last quarter 2026. Already have a position, but getting interesting to add more. Once good results in phase 3, the risk reduces to make this a true biotech.
1 · Reply
Stocksman45
Stocksman45 Jun. 6 at 12:02 PM
$IMAB Nice that they look like they are skipping to phase 3 for Givastomig. Possibly by year end. “Givastomig, a potential best-in-class/first-in-class Claudin 18.2-directed bispecific antibody for gastric cancer, has shown robust and durable responses with broad CLDN18.2 activity, favorable safety, as well as potential eligibility for FDA’s Accelerated Approval Pathway with potential initiation of a registrational Phase 3 trial as early as Q4 2026.”
0 · Reply
GamblingFerret
GamblingFerret Jun. 6 at 11:25 AM
$IMAB Partner ABL Bio has initiated Ragistomig combination cohort (Phase 1)
0 · Reply
GamblingFerret
GamblingFerret Jun. 3 at 7:49 PM
$IMAB Tomorrow at Jefferies Healthcare Conference. I would not be surprised if we get Q1 results today after hours or tomorrow pre-market.
0 · Reply
GamblingFerret
GamblingFerret May. 29 at 10:25 PM
$IMAB Even though Nova is not at ASCO, there are still potential triggers. https://www.asco.org/annual-meeting/search?filters=%7B%22mediaTypes%22:%5B%22Abstracts%22%5D%7D&userInput=Claudin%2018.2&sortBy=AbstractBrowse&contentKey=ANNUAL_MEETING&contentKeyYear=2026 Multiple presentations of Claudin 18.2 ADCs, combinations and Bispecifics. I checked them quickly, benefits for Giva in PFS, ORR, safety and low claudin concentration depending on competitors. Hope with quarterly report we receive an update from 12mg cohort, especially on PFS which will most likely exceed the 16.9 months from 8mg cohort based on 6 month landmark. As reminder: https://www.novabridge.com/news-releases/news-release-details/novabridge-presents-positive-givastomig-dose-expansion-data Overall it looks like Giva prooves to be best in class with broadest spectrum.
1 · Reply
GamblingFerret
GamblingFerret May. 20 at 5:49 AM
$IMAB Worth listening to HC Wainwright fireside chat with focus on Giva Nova finalizes Giva Phase 3 design and intends to start in Q4. Interesting comment from Sean, I expect a partnering after design approval and update of running extension cohorts. Interesting as well: They are evaluating to start a Claudin 18.2 negativ cohort given the strong performance of Giva in low CLD 18.2 patient and test inaccuracy in extreme low settings. This would add additional 25-30% of total market opportunity. Double low, BTC and PDAC chorts recruiting well with data expected YE.
1 · Reply
LabPsycho
LabPsycho May. 15 at 8:12 PM
$IMAB @Tika1 @jayshree4201Twits Unless nobody cares. I am not seeing any huge differentiator with their data...looks good but going to need more than that IMO. And this opinion applies to many biotechs - while it might seem early, some of these that have drifted down since the beginning of the year I see more downward movement motivated by: Summer doldrums (sell in May then go away) Blips in June (ASCO conference spiking 1 or 2) Drifting down more Spikes in Sept (transient for a few) Nov. Tax loss selling I could see NBP IMAB getting down to 1.2 by then. Dec - Feb 2027 some up 100-200% if one times the bottom perfectly + a bit of luck
1 · Reply
jayshree4201Twits
jayshree4201Twits May. 11 at 7:20 PM
$IMAB Anyone still around for this stock? Since NBP is taken, seems like no one is holding this. Anyone has any thought they can share regarding current movement?
2 · Reply
Stocksman45
Stocksman45 Apr. 9 at 1:40 PM
$IMAB “Givastomig, a potential best-in-class/first-in-class Claudin 18.2-directed bispecific antibody for gastric cancer, has shown robust and durable responses with broad CLDN18.2 activity, favorable safety, as well as potential eligibility for FDA’s Accelerated Approval Pathway with potential initiation of a registrational Phase 3 trial as early as Q4 2026” Accelerated Phase 3? This sounds like a very promising development.
0 · Reply
FF355
FF355 Apr. 7 at 4:10 AM
$IBRX all in $NBP.X $IMAB Will thank me
0 · Reply
LabPsycho
LabPsycho Mar. 30 at 3:18 PM
$IMAB Like I posted about 2 weeks ago when this was $3 ish. Data looks good but not seeing a big differentiator here...and the location now.
0 · Reply
LabPsycho
LabPsycho Mar. 19 at 2:30 PM
$IMAB IMO, I am not seeing significant product differentiation for either of their drugs. Maybe a little better but could get lost in the crowd. And I do not know if I am understanding but did they move from Asia to USA back to Hong Kong? Watching but I think this like many biotechs going to be giving up their 50-1200% gains the past 11 months. I'd like to see these get well below cash like the good ole days. Valuations and risk / reward, esp. with war and inflation increasing not a good look currently IMO
1 · Reply
GamblingFerret
GamblingFerret Mar. 19 at 2:24 PM
$IMAB Remarkable news lately: Novabridge and FDA aligned on potential accelerated approval path for Givastomig. Phase 3 is intended to start in Q4 2026 based on phase 1b data. The recently started phase 2 was intended to deliver data in mid 2027, so this news speeds up development at least 1 year. Giva has market potential of roughly 5 billion, Novabridge owns 50% of the Asset and is in development lead. https://www.novabridge.com/news-releases/news-release-details/novabridge-announces-productive-fda-type-b-meeting-potential
0 · Reply
aletz
aletz Mar. 13 at 10:31 AM
$IMAB https://www.biostockinfo.com/biotech-catalyst-ai-scanner-march-wk3/ #5 pick for March Week 3. Visit the link for more detail.
1 · Reply
Stocksman45
Stocksman45 Mar. 10 at 11:49 PM
$IMAB very good news on their new acquisition the eye drug yesterday. And of course their mainstay Givistomag is the big gun.
0 · Reply
sgtcw1
sgtcw1 Mar. 5 at 4:50 PM
$IMAB not a bad day!
0 · Reply
Stocksman45
Stocksman45 Feb. 9 at 8:43 PM
$IMAB Very detailed presentation on Novabridge Biosciences. Worth a read: https://archive.fast-edgar.com/20260206/AU22J22CZZ2RI2Z2229N2CYQGRPH4Z22D282/nbp-ex99_1.htm
0 · Reply
Stocksman45
Stocksman45 Jan. 27 at 5:45 PM
$IMAB Lots of insider buying. News forthcoming in the next month or so?
0 · Reply
sgtcw1
sgtcw1 Jan. 20 at 2:34 PM
$IMAB https://finance.yahoo.com/news/novabridge-announces-open-market-purchases-120000363.html
0 · Reply
HephaestusH
HephaestusH Dec. 27 at 4:46 AM
$IMAB Expectations are resetting toward sustainable results, not one‑off wins. Governance alignment can reduce perceived uncertainty. If milestones become dependable, sentiment could re‑rate quickly. Ultimately, disciplined delivery will shape the outcome.
0 · Reply